{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:45:17Z","timestamp":1767167117198,"version":"build-2238731810"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1124\/dmd.32.4.398","type":"journal-article","created":{"date-parts":[[2004,3,23]],"date-time":"2004-03-23T17:08:14Z","timestamp":1080061694000},"page":"398-404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["COMPARISON OF PREDICTION METHODS FOR IN VIVO CLEARANCE OF (S,S)-3-[3-(METHYLSULFONYL)PHENYL]-1-PROPYLPIPERIDINE HYDROCHLORIDE, A DOPAMINE D2 RECEPTOR ANTAGONIST, IN HUMANS"],"prefix":"10.1016","volume":"32","author":[{"given":"Shinji","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa N.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith L.","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Neil","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.32.4.398_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1600-0773.1986.tb00142.x","article-title":"In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man.","volume":"59","author":"B\u00e4\u00e4rnhielm","year":"1986","journal-title":"Acta Pharmacol Toxicol"},{"key":"10.1124\/dmd.32.4.398_bib2","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1042\/bst0181198","article-title":"Prediction of intrinsic clearance of loxtidine from kinetic studies in rat, dog and human hepatocytes.","volume":"18","author":"Bayliss","year":"1990","journal-title":"Biochem Soc Trans"},{"key":"10.1124\/dmd.32.4.398_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF01065191","article-title":"Interspecies variation in liver weights, hepatic blood flow and antipyrine intrinsic clearance in extrapolation of data to benzodiazepines and phenytoin.","volume":"8","author":"Boxenbaum","year":"1980","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.32.4.398_bib4","series-title":"Advances in Drug Research","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/B978-0-12-013319-2.50006-1","article-title":"Interspecies pharmacokinetic scaling, biological design and neoteny","author":"Boxenbaum","year":"1990"},{"key":"10.1124\/dmd.32.4.398_bib5","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans.","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res (NY)"},{"key":"10.1124\/dmd.32.4.398_bib6","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1097\/00001756-199707280-00029","article-title":"(-)-OSU6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinsons disease.","volume":"8","author":"Ekesbo","year":"1997","journal-title":"Neuroreport"},{"key":"10.1124\/dmd.32.4.398_bib7","series-title":"Pharmacokinetics, 2nd ed.","author":"Gibaldi","year":"1982"},{"key":"10.1124\/dmd.32.4.398_bib8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0022-3565(25)30967-5","article-title":"Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration.","volume":"202","author":"Greenblatt","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.32.4.398_bib9","series-title":"Cytochrome P450: Structure, Mechanism and Biochemistry","first-page":"473","article-title":"Human cytochrome P450 enzymes","author":"Guengerich","year":"1995"},{"key":"10.1124\/dmd.32.4.398_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1081\/DMR-100100564","article-title":"Cryoperserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction.","volume":"32","author":"Hengstler","year":"2000","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.32.4.398_bib11","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/0006-2952(94)90520-7","article-title":"Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.","volume":"47","author":"Houston","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.32.4.398_bib12","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3109\/00498259009046839","article-title":"Interspecies scaling and comparisons in drug development and toxicokinetics.","volume":"20","author":"Ings","year":"1990","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.32.4.398_bib13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev.pharmtox.38.1.461","article-title":"Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport.","volume":"38","author":"Ito","year":"1998","journal-title":"Annu Rev Pharmcol Toxicol"},{"key":"10.1124\/dmd.32.4.398_bib14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/(SICI)1099-081X(199605)17:4<273::AID-BDD961>3.0.CO;2-R","article-title":"Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics.","volume":"17","author":"Iwatsubo","year":"1996","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.32.4.398_bib15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00003088-199936030-00003","article-title":"Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlation.","volume":"36","author":"Lave","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.32.4.398_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0009-2797(99)00088-5","article-title":"Cyropreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability and drug-drug interaction potential.","volume":"121","author":"Li","year":"1999","journal-title":"Chem-Biol Interact"},{"key":"10.1124\/dmd.32.4.398_bib17","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3109\/00498259609052491","article-title":"Interspecies scaling: predicting clearance of drugs in humans. Three different approaches.","volume":"9","author":"Mahmood","year":"1996","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.32.4.398_bib18","series-title":"Pharmaceutical Bioequivalence, vol 48","first-page":"267","article-title":"Interspecies scaling in pharmacokinetics","author":"McNamara","year":"1991"},{"key":"10.1124\/dmd.32.4.398_bib19","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/jps.2600751104","article-title":"Man vs beast: pharmacokinetic scaling in mammals.","volume":"75","author":"Mordenti","year":"1986","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.32.4.398_bib20","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1015836720294","article-title":"Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins.","volume":"8","author":"Mordenti","year":"1991","journal-title":"Pharm Res (NY)"},{"key":"10.1124\/dmd.32.4.398_bib21","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1124\/dmd.31.5.580","article-title":"Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro.","volume":"31","author":"Naritomi","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.32.4.398_bib22","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/0016-5085(90)91150-5","article-title":"The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids.","volume":"99","author":"Oberle","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1124\/dmd.32.4.398_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/019262339602400107","article-title":"An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials.","volume":"24","author":"Parkinson","year":"1996","journal-title":"Toxicol Pathol"},{"key":"10.1124\/dmd.32.4.398_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0742-8413(92)90003-P","article-title":"The allometric approach for interspecies scaling of pharmacokinetic parameters.","volume":"103","author":"Ritschel","year":"1992","journal-title":"Comp Biochem Physiol C"},{"key":"10.1124\/dmd.32.4.398_bib25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF01106706","article-title":"A dispersion model of hepatic elimination. 1. Formulation of the model and bolus considerations.","volume":"14","author":"Roberts","year":"1986","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.32.4.398_bib26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF01061720","article-title":"Prediction of the disposition of beta-lactam antibiotics in humans from pharmacokinetic parameters in animals.","volume":"12","author":"Sawada","year":"1984","journal-title":"J Pharmacokinet Biopharmacol"},{"key":"10.1124\/dmd.32.4.398_bib27","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00004714-198208000-00008","article-title":"Bioavailability of intramuscular versus oral haloperidol in schizophrenic patients.","volume":"2","author":"Schaffer","year":"1982","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/dmd.32.4.398_bib28","first-page":"286","article-title":"Pharmacokinetics of OSU-6162 and its desalkyl metabolite in the rat and dog.","volume":"32","author":"Shobe","year":"2000","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.32.4.398_bib29","first-page":"2098","article-title":"Metabolism and disposition of OSU-6162 in rats and dogs.","volume":"1","author":"Sood","year":"1999","journal-title":"AAPS Pharm Sci Suppl"},{"key":"10.1124\/dmd.32.4.398_bib30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF02017693","article-title":"Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy.","volume":"5","author":"Stockly","year":"1986","journal-title":"Eur J Clin Microbiol"},{"key":"10.1124\/dmd.32.4.398_bib31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0378-4274(95)03488-9","article-title":"Applications and prospects for physiologically based pharmacokinetic (PK-PB) models involving pharmaceutical agents.","volume":"82\/83","author":"Suzuki","year":"1995","journal-title":"Toxicol Lett"},{"key":"10.1124\/dmd.32.4.398_bib32","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/(SICI)1098-2396(199804)28:4<280::AID-SYN3>3.0.CO;2-5","article-title":"Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity.","volume":"28","author":"Tedroff","year":"1998","journal-title":"Synapse"},{"key":"10.1124\/dmd.32.4.398_bib33","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3109\/00498259509061925","article-title":"Bosentan, a new endothelin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data.","volume":"25","author":"Ubeaud","year":"1995","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.32.4.398_bib34","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1124\/dmd.30.12.1372","article-title":"Multiple cytochrome P450 enzymes responsible for the oxidative metabolism of the substituted (S)-3-phenylpiperidine, (S,S)-3-[3-(methylsulfonyl)-phenyl]-1-propylpiperidine hydrochloride, in human liver microsomes.","volume":"30","author":"Wienkers","year":"2002","journal-title":"Drug Metab Dispos"}],"updated-by":[{"DOI":"10.1124\/dmd.32.10.1199","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000}}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624028873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624028873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.32.4.398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T11:56:33Z","timestamp":1739879793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624028873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S0090955624028873"],"URL":"https:\/\/doi.org\/10.1124\/dmd.32.4.398","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COMPARISON OF PREDICTION METHODS FOR IN VIVO CLEARANCE OF (S,S)-3-[3-(METHYLSULFONYL)PHENYL]-1-PROPYLPIPERIDINE HYDROCHLORIDE, A DOPAMINE D2 RECEPTOR ANTAGONIST, IN HUMANS","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.32.4.398","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2004 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}